𝔖 Bobbio Scriptorium

✦ LIBER ✦

P79 Outcome research in angina pectoris: Limitations of some phase III trials

✍ Scribed by Sylvie Ahn; Michel F. Rousseau; Hubert Pouleur

Book ID: 113298349
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 77 KB
Volume: 16
Category: Article
ISSN: 0197-2456
DOI: 10.1016/0197-2456(95)90559-n

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P59 Are there differences in outcome of

P59 Are there differences in outcome of patients with unstable angina pectoris Braunwald class III versus Braunwald classes I/II treated with coronary angioplasty

📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Interruptions of once-daily thoracic rad

Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: Analysis of CALGB phase III trial 9235

✍ Bogart, Jeffrey A.; Watson, Dorothy; McClay, Edward F.; Evans, Lisa; Herndon, Ja 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 221 KB

P-514 Can baseline quality of life param

P-514 Can baseline quality of life parameters predict survival and other efficacy outcomes in malignant pleural mesothelioma?: Results from a 448-patient phase III trial

✍ Gralla, R.J.; Symanowski, J.T.; Liepa, A.M.; Boyer, M.J.; Ruffie, P.; Moro-Sibil 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 193 KB

P-225 XPD and RRM1 gene polymorphisms pr

P-225 XPD and RRM1 gene polymorphisms predict gemcitabine (gem)/cisplatin (cis)/docetaxel (doc) outcome in stage III non-small-cell lung cancer (NSCLC): a genetic analysis of the Spanish Lung Cancer Group phase II trial 9901

✍ Sarries, Carme; Garrido, Pilar; Nun˜ez, Laura; Roig, Barbara; Ramirez, Jose Luis 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 178 KB

P.39 Docetaxel plus epirubicin (DE) vs d

P.39 Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Vamvakas, L.; Karampeazis, A.; Ardavanis, A.; Souglakos, I.; Kalbakis, K.; Varda 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Randomized phase II/III trial of interfe

Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951): Aass N, De Mulder PHM, Mickisch GHJ, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ, Department of Clinical Cancer Research, The Norwegian Radium Hospital, Oslo, Norway

✍ Robert Flanigan 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 42 KB